Stelios Papadopoulos - May 16, 2024 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role: Director
Signature: Christopher Aker, Attorney in Fact
Stock symbol: RGLS
Transactions as of: May 16, 2024
Transactions value $: $0
Form type: 4
Date filed: 5/17/2024, 04:38 PM
Previous filing: Mar 15, 2024
Next filing: May 21, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RGLS	Stock Option (Right to Buy)	Award	$0	+30K		$0.00	30K	May 16, 2024	Common Stock	30K	$2.01	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service.

Content

Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service.